ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2892

Model-based Cost-Effectiveness Analyses Comparing Combinations of Urate Lowering Therapy and Anti-Inflammatory Treatment in Newly Diagnosed Gout Patients

Celine van de Laar1, Martijn A.H. Oude Voshaar 2, Carly Janssen 3, Matthijs Janssen 4, Maiwenn Al 5 and Mart A.F.J. van de Laar 6, 1Transparency in Healthcare B.V., Hengelo, Overijssel, Netherlands, 2Transparency in Healthcare B.V. and Department of Psychology, Health & Technology, University of Twente, Hengelo, Netherlands, 3Department of Psychology, Health & Technology, University of Twente, Enschede, Netherlands, 4Department of Rheumatology, VieCuri Medical Center, Venlo, Netherlands, 5Erasmus University Rotterdam, Rotterdam, Netherlands, 6Arthritis Center Twente, Enschede, Netherlands

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: gout, Heath Economics and cost-effectiveness

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Wednesday, November 13, 2019

Session Title: 6W017: Health Services Research II: Health Economics (2888–2893)

Session Type: ACR/ARP Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: To assess the cost-effectiveness of various combinations of urate lowering therapy (ULT) and anti-inflammatory treatment in the management of newly diagnosed gout patients, from the Dutch societal perspective. 

Methods: The Anakinra versus Treatment as usual in the Treatment of ACute Gout (ATTACG) study was the  primary data source for  this study.  Since only patients with crystal proven gout were included in that study, all patient satisfy the ACR/EULAR gout classification criteria.

A probabilistic patient-level simulation estimating costs and quality-adjusted life years (QALYs) was performed to compare gout and hyperuricemia treatment strategies. Pain was the  main determinant of both QALYs and costs, with disutility assigned to patients who failed to reach the serum urate (SUA) target (< 0.36 mmol/L). Patients faced a daily risk of a gout flare, with a higher risk for patients who failed to achieve the SUA target level. Health states were no flare, severe pain, mild pain, moderate pain, or no pain in the presence of a flare. Model input was derived from patient level clinical trial data (i.e. SF-6D utility, indirect costs in €’s and pain transition probabilities), meta-analyses or from previously published health-economic evaluations. The results of probabilistic sensitivity analyses were presented using incremental cost-effectiveness ratios (ICERs), and summarized using cost-effectiveness acceptability curves (CEAC). Scenario analyses were performed for gout patients not necessarily experiencing a gout flare at model entry, and for patients with a higher daily flare probability.

Results: In the base case, the ICER for allopurinol versus no ULT was €1,381, when combined with naproxen. Febuxostat yielded the highest utility but also the highest costs (€4,385 vs. €4,063 for allopurinol), resulting in an ICER of €25,173 when compared to allopurinol, all combined with naproxen. No ULT with naproxen was not cost-effective, yielding the lowest utility. For the gout flare medications, comparable effects on utility were achieved. Combined with allopurinol, naproxen was the cheapest option (€4,051), and anakinra the most expensive (€4,299). The ICER of anakinra compared to naproxen, when combined with allopurinol was €1,003,805.67 . Colchicine and prednisone were dominated by naproxen when combined with any of the ULT options. Results of the scenario analyses did not change the conclusions drawn from comparison of ULT and anti-inflammatory treatment. Results remained robust in scenario analyses.

Conclusion: Allopurinol and febuxostat were both cost-effective compared to No ULT. Febuxostat was cost-effective when compared to allopurinol in case of higher willingness-to-pay thresholds. Anakinra was not cost-effective at any regularly acceptable willingness-to-pay threshold. For treating acute gout flares, colchicine, naproxen and prednisone offered comparable health economic implications. However, naproxen was the favoured and dominant option.

QALY = Quality adjusted life years; ICER = incremental cost-effectiveness ratio; ULT = urate lowering therapy;

QALY = Quality adjusted life years; ICER = incremental cost-effectiveness ratio; ULT = urate lowering therapy;

ULT = urate lowering therapy; WTP = willingness-to-pay. Figure displays the CEAC for different ULT combined with naproxen as the anti-inflammatory agent.


Disclosure: C. van de Laar, None; M. Oude Voshaar, Swedish Oprhan Biovitrum AB, 2, Grünenthal B.V., 2; C. Janssen, Grünenthal B.V., 2, Swedish Oprhan Biovitrum AB, 2; M. Janssen, Grünenthal B.V., 8; M. Al, None; M. van de Laar, Abbvie, 2, 5, Eli Lilly and Company, 2, 5, 8, Merck, 2, 5, Pfizer, 2, 5, 8, Sanofi Genzym, 5, Grünenthal B.V., 2, Swedish Oprhan Biovitrum AB, 2.

To cite this abstract in AMA style:

van de Laar C, Oude Voshaar M, Janssen C, Janssen M, Al M, van de Laar M. Model-based Cost-Effectiveness Analyses Comparing Combinations of Urate Lowering Therapy and Anti-Inflammatory Treatment in Newly Diagnosed Gout Patients [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/model-based-cost-effectiveness-analyses-comparing-combinations-of-urate-lowering-therapy-and-anti-inflammatory-treatment-in-newly-diagnosed-gout-patients/. Accessed January 20, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/model-based-cost-effectiveness-analyses-comparing-combinations-of-urate-lowering-therapy-and-anti-inflammatory-treatment-in-newly-diagnosed-gout-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.